Compare FLOC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLOC | PHAT |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 806.0M | 676.3M |
| IPO Year | 2024 | 2019 |
| Metric | FLOC | PHAT |
|---|---|---|
| Price | $18.48 | $7.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $28.50 | $19.83 |
| AVG Volume (30 Days) | 490.5K | ★ 1.1M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $759,719,000.00 | $175,110,000.00 |
| Revenue This Year | $22.92 | $93.04 |
| Revenue Next Year | $8.59 | $58.91 |
| P/E Ratio | $36.50 | ★ N/A |
| Revenue Growth | 41.93 | ★ 216.93 |
| 52 Week Low | $14.03 | $6.91 |
| 52 Week High | $28.26 | $18.31 |
| Indicator | FLOC | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 32.63 | 36.45 |
| Support Level | $17.60 | N/A |
| Resistance Level | $24.32 | $9.74 |
| Average True Range (ATR) | 0.84 | 0.40 |
| MACD | -0.16 | -0.05 |
| Stochastic Oscillator | 2.61 | 20.57 |
Flowco Holdings Inc is a provider of production optimization, artificial lift, emissions management, and monetization solutions for the oil and natural gas industry. Its technologies include high-pressure gas lift (HPGL), conventional gas lift, plunger lift, and vapor recovery unit (VRU) solutions. The company operates in two reportable segments: Production Solutions, which includes rental services, and Natural Gas Technologies, which include service, gas compression parts, and equipment sales. Production Solutions: relates to rentals, sales, and services related to high-pressure gas lift, conventional gas lift, and plunger lift; including other digital solutions and methane abatement technologies, and has maximum revenue. It generates maximum revenue from the United States.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.